We need a better marker for prostate cancer. How about renaming PSA?

Urology

Volumn 79, Issue 2, 2012, Pages 254-255

  Vickers, Andrew J ^a   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SARCOSINE;

BREAST CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; GENE LOCUS; HEALTH CARE; HUMAN; INDIA; NOTE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84856738246     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.10.058     Document Type: Article

References (25)

1. Making better use of PSA testing http://www.everydayhealth.com/blog/ health-in-the-news/2010/09/23/making-better-use-of-psa-testing/ Accessed July 21, 2011
2. Single PSA test at age 60 provides an indication of future prostate cancer risk http://info.cancerresearchuk.org/news/archive/cancernews/2010-09-16- Single-PSA-test-at-age-60-provides-an-indication-of-future-prostate-cancer-risk- Accessed July 21, 2011
3. G.L. Andriole Jr Screening for prostate cancer BMJ 341 2010 c4538
4. DNA test may aid PCa detection http://www.renalandurologynews.com/dna- test-may-aid-pca-detection/article/173047/# Accessed July 21, 2011
5. U.H. Stenman, M. Hakama, P. Knekt Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer Lancet 344 1994 1594 1598 (Pubitemid 24365358)
6. A.J. Vickers, A.M. Cronin, T. Bjrk Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
7. H.B. Carter, L. Ferrucci, A. Kettermann Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 2006 1521 1527 (Pubitemid 44680903)
8. H. Lilja, A.M. Cronin, A. Dahlin Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 2011 1210 1219
9. S. Wacholder, P. Hartge, R. Prentice Performance of common genetic variants in breast-cancer risk models N Engl J Med 362 2010 986 993
10. A. Vickers, H. Lilja, P. Scardino Five genetic variants associated with prostate cancer N Engl J Med 358 2008 2740 [author reply 2741] (Pubitemid 351860882)
11. National Human Genome Research Project Personalized Medicine: How the Human Genome Era Will Usher in a Health Care Revolution http://www.genome.gov/ 13514107 Accessed July 21, 2011
12. A. Sreekumar, L.M. Poisson, T.M. Rajendiran Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 457 2009 910 914
13. F. Jentzmik, C. Stephan, K. Miller Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours Eur Urol 58 2010 12 18 [discussion 20-21]
14. F. Jentzmik, C. Stephan, M. Lein Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression J Urol 185 2011 706 711
15. T.A. Stamey, M. Caldwell, J.E. McNeal The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172 2004 1297 1301 (Pubitemid 39249701)
16. I.M. Thompson, D.P. Ankerst, C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 2005 66 70 (Pubitemid 41002840)
17. M. Djulbegovic, R.J. Beyth, M.M. Neuberger Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials BMJ 341 2010 c4543
18. New EPCA-2 prostate cancer test far more accurate than discredited PSA test http://www.naturalnews.com/020125.html Accessed July 21, 2011
19. A.W. Roddam, M.J. Duffy, F.C. Hamdy Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386 399 [discussion 398-399]
20. W.J. Catalona, G. Bartsch, H.G. Rittenhouse Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen J Urol 171 2004 2239 2244 (Pubitemid 38625443)
21. T. Steuber, P. Nurmikko, A. Haese Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen J Urol 168 2002 1917 1922
22. W.J. Catalona, A.W. Partin, M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650 1655
23. A. Vickers, A. Cronin, M. Roobol Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
24. A. Gupta, M.J. Roobol, C.J. Savage A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands Br J Cancer 103 2010 708 714
25. S.A. Strope, G.L. Andriole Improving prostate-specific antigen screening J Clin Oncol 28 2010 2491 2492